Summary:
In adults with HFpEF (EF ≥50%), obesity (BMI ≥30 kg/m²), stratified by presence or absence of type 2 diabetes from the SUMMIT trial, tirzepatide (up to 15 mg weekly) for 52 weeks demonstrated similar reduction in the composite of cardiovascular death or worsening heart failure events regardless of diabetes status with consistent improvements in KCCQ scores, 6-minute walk distance, and cardiac structure compared to placebo, with modestly attenuated weight loss in patients with diabetes (approximately 12-13% vs 15% without diabetes) though still clinically meaningful.
| PICO | Description |
|---|---|
| Population | Adults with HFpEF (EF ≥50%), obesity (BMI ≥30 kg/m²), stratified by presence or absence of type 2 diabetes, from the SUMMIT trial. |
| Intervention | Tirzepatide (up to 15 mg weekly) for 52 weeks. |
| Comparison | Placebo. |
| Outcome | Similar reduction in CV death/worsening HF regardless of diabetes status. Consistent improvements in symptoms, function, and cardiac structure. Modestly attenuated weight loss in diabetes. |
Tirzepatide in HFpEF + obesity: does diabetes matter?
RCT subgroup · HFpEF + obesity · SUMMIT
Tirzepatide cut CV death or worsening HF events by a similar degree with and without type 2 diabetes (interaction P=0.95), despite less weight loss in the diabetes subgroup.
Clinical Context
Heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes frequently coexist, sharing obesity and insulin resistance as common pathophysiological drivers.
Clinical Pearls
1. Consistent Benefits Despite Diabetes: The heart failure benefits of tirzepatide in obese HFpEF are preserved in patients with type 2 diabetes.
2. Weight Loss Attenuation Expected but Not Limiting: Patients with diabetes achieved somewhat less weight loss but heart failure benefits were preserved.
3. Cardiac Structural Benefits Consistent: Reductions in left ventricular mass and pericardial fat were similar regardless of diabetes status.
4. Glycemic Control Added Benefit: Patients with diabetes receiving tirzepatide achieved significant HbA1c reductions in addition to heart failure benefits.
Practical Application
For patients with the obesity-HFpEF-diabetes triad, tirzepatide offers a compelling treatment option addressing all three conditions. Consider SGLT2 inhibitors as complementary therapy.
Study Limitations
Subgroup analysis has less statistical power than the main trial. Duration of 52 weeks may not capture long-term outcomes.
Bottom Line
Tirzepatide provides consistent heart failure benefits in obese HFpEF patients regardless of diabetes status.
Source: Packer M, et al. “Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.” Read article